A Scientific Perspective on Standards, Variability, and Scientific Accountability

Medicine presents itself as science. But science, in its classical sense, requires measurement — precise, reproducible, and independently verifiable measurement. Without that, claims remain narratives.

Let us begin with a thought experiment. Suppose the medical establishment were to declare: “We made a mistake. The viral model, as currently defined, lacks foundational verification.” What would follow? Entire segments of modern pharmaceutical practice — particularly the vaccine sector — are built upon specific biological premises. If those premises were fundamentally revised, the products derived from them would require re-evaluation. The point is not collapse. The point is dependence. The industry operates within a framework defined by what is called “medical science.”

Now consider something more concrete.

Pharmaceutical products are chemical entities. Their identity, purity, stability, structure, and performance are chemical questions. These are not medical questions. They are questions of chemistry. Yet pharmaceutical oversight is largely conducted under regulatory and medical frameworks rather than under strictly chemical standards. If these products were evaluated solely by the standards of classical analytical chemistry, many would face far more rigorous scrutiny.

The difference is not philosophical. It is measurable.

In 1999 (see below), I conducted an international collaborative study involving 28 laboratories that assessed the drug-release characteristics of tablet formulations using dissolution testing — widely regarded as the gold standard in pharmaceutical evaluation. The variability among laboratories ranged from 17% to 37% coefficient of variation. This was a purely chemical test. No biological variability was involved.

From a strict chemical perspective, such variability would raise immediate concern. In analytical chemistry, reproducibility at that level would be questioned, investigated, and corrected. Yet within pharmaceutical practice, such variation was treated as acceptable.

This is not a minor technical detail. It reflects a structural difference in standards.

In chemistry, precision, accuracy, and reproducibility are non-negotiable. Methods must yield consistent results across laboratories. Materials must be fully characterized. Measurements must be traceable and independently verifiable. In medical science, however, higher degrees of variability are often normalized. Methodological looseness becomes institutionalized. Statistical tolerance replaces analytical certainty.

Even more concerning, this variability is rarely communicated openly. Products are promoted under the banner of “rigorous science,” while the underlying measurement standards would not meet classical chemical expectations. Many clinicians and medical researchers may not even recognize this discrepancy. They operate within a system whose standards were historically defined in medicine rather than grounded in foundational physical science.

This structural issue becomes even more consequential when one considers vaccine evaluation.

Vaccines — whether traditional formulations or newer genetic platforms — are chemical products. They contain defined molecular components: proteins, nucleic acids, lipids, stabilizers, and excipients. Each of these components should, in principle, be subject to the same rigorous standards applied in chemistry: full structural characterization, verified purity, batch-to-batch reproducibility, independent analytical confirmation, and clearly established reference standards.

If variability in a relatively simple tablet dissolution test can reach double-digit coefficients of variation across laboratories, one must reasonably ask what reproducibility standards apply to far more complex biological formulations. Are molecular contents fully characterized and independently verified? Are reference standards publicly accessible and traceable? Is analytical variability openly disclosed?

These are not anti-vaccine questions. They are pro-measurement questions.

If medicine wishes to invoke the authority of science, then vaccine evaluation must withstand the same level of analytical rigor expected in chemistry. Otherwise, the evaluation process rests more on regulatory acceptance and statistical modeling than on strict physical verification.

The question, therefore, is not whether medicine should exist. The question is whether medicine is willing to submit itself fully to the standards of the physical sciences upon which it ultimately depends. Until rigorous measurement becomes central, medicine risks remaining science in name — as it largely presents itself today — but not in method, nor in a truly scientific approach.

  1. Qureshi, S. A., & McGilveray, I. J. (1999). Typical variability in drug dissolution testing: Study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product. European Journal of Pharmaceutical Sciences, 7(3), 249–258.
  2. Qureshi, S. A., & McGilveray, I. J. (1998). Assessment of pharmaceutical quality of furosemide tablets from multinational markets. Drug Development and Industrial Pharmacy, 24(11), 995–1005.
  3. Variability and unpredictability, everywhere! (link )